ArticlePloS one2015
Future Economics of Liver Transplantation: A 20-Year Cost Modeling Forecast and the Prospect of Bioengineering Autologous Liver Grafts.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Barriers and facilitators of deceased organ donation among Pakistanis living globally: a systematic review.BMJ open · 2025Pooled it
- A pragmatic outreach pilot to understand and overcome barriers to COVID-19 vaccination in abdominal organ transplant.Transplant infectious disease : an official journal of the Transplantation Society · 2021Trial
- The Spanish transplantation model as a benchmark: clinical, societal, and economic impact of liver transplants in Spain (1984-2024).Health economics review · 2026Article
- Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.Portal hypertension & cirrhosis · 2026Review
- Article
- Predictors of health-seeking behavior in patients with chronic liver disease and a comparison of health-seeking based on patient-type.BMC gastroenterology · 2025Article
- Interlacing biology and engineering: An introduction to textiles and their application in tissue engineering.Materials today. Bio · 2025Review
- The emerging role of alternatively activated macrophages to treat acute liver injury.Archives of toxicology · 2025Review
- Ethical frontiers in liver transplantation.World journal of transplantation · 2024Review
- Beyond 75: Graft Allocation and Organ Utility Implications in Liver Transplantation.Transplantation direct · 2024Article
- Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction.Biomaterials research · 2024Review
- Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.Gastro hep advances · 2024Article
- HLA-based banking of induced pluripotent stem cells in Saudi Arabia.Stem cell research & therapy · 2023Article
- Perspectives on Scaffold Designs with Roles in Liver Cell Asymmetry and Medical and Industrial Applications by Using a New Type of Specialized 3D Bioprinter.International journal of molecular sciences · 2023Article
- Article
- Profile of Liver Transplant Recipient in a Tertiary Hospital in Northern Spain.Journal of clinical medicine · 2023Article
- Acute pancreatitis in liver transplant hospitalizations: Identifying national trends, clinical outcomes and healthcare burden in the United States.World journal of hepatology · 2023Article
- Widespread Community Transmission of Hepatitis A Virus Following an Outbreak at a Local Restaurant - Virginia, September 2021-September 2022.MMWR. Morbidity and mortality weekly report · 2023Article
- Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection.Science translational medicine · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
During the past 20 years liver transplantation has become the definitive treatment for most severe types of liver failure and hepatocellular carcinoma, in both children and adults. In the U.S., roughly 16,000 individuals are on the liver transplant waiting list. Only 38% of them will receive a transplant due to the organ shortage. This paper explores another option: bioengineering an autologous liver graft. We developed a 20-year model projecting future demand for liver transplants, along with costs based on current technology. We compared these cost projections against projected costs to bioengineer autologous liver grafts. The model was divided into: 1) the epidemiology model forecasting the number of wait-listed patients, operated patients and postoperative patients; and 2) the treatment model forecasting costs (pre-transplant-related costs; transplant (admission)-related costs; and 10-year post-transplant-related costs) during the simulation period. The patient population was categorized using the Model for End-Stage Liver Disease score. The number of patients on the waiting list was projected to increase 23% over 20 years while the weighted average treatment costs in the pre-liver transplantation phase were forecast to increase 83% in Year 20. Projected demand for livers will increase 10% in 10 years and 23% in 20 years. Total costs of liver transplantation are forecast to increase 33% in 10 years and 81% in 20 years. By comparison, the projected cost to bioengineer autologous liver grafts is $9.7M based on current catalog prices for iPS-derived liver cells. The model projects a persistent increase in need and cost of donor livers over the next 20 years that's constrained by a limited supply of donor livers. The number of patients who die while on the waiting list will reflect this ever-growing disparity. Currently, bioengineering autologous liver grafts is cost prohibitive. However, costs will decline rapidly with the introduction of new manufacturing strategies and economies of scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.